Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $392.3 million.

  • Ocular Therapeutix's Net Cash Flow rose 121705.68% to $392.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $345.0 million, marking a year-over-year increase of 7586.89%. This contributed to the annual value of $345.0 million for FY2025, which is 7586.89% up from last year.
  • Ocular Therapeutix's Net Cash Flow amounted to $392.3 million in Q4 2025, which was up 121705.68% from -$46.4 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Net Cash Flow high stood at $392.3 million for Q4 2025, and its period low was -$46.4 million during Q3 2025.
  • Moreover, its 5-year median value for Net Cash Flow was -$16.3 million (2021), whereas its average is $25.4 million.
  • Per our database at Business Quant, Ocular Therapeutix's Net Cash Flow tumbled by 19719.97% in 2021 and then surged by 133348.37% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Net Cash Flow stood at -$15.1 million in 2021, then fell by 23.37% to -$18.6 million in 2022, then surged by 557.14% to $85.3 million in 2023, then plummeted by 141.19% to -$35.1 million in 2024, then soared by 1217.06% to $392.3 million in 2025.
  • Its Net Cash Flow was $392.3 million in Q4 2025, compared to -$46.4 million in Q3 2025 and $41.5 million in Q2 2025.